How Morphometric Analysis of Metastatic Load Predicts the (un)usefulness of PET Scanning: the Case of Lymph Node Staging in Melanoma

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2003 Mar 29

PMID 12663640

Citations 4

Authors

G S Mijnhout

O S Hoekstra

A van Lingen

P J van Diest

H J Ader

A A Lammertsma

R Pijpers

S Meijer

G J J Teule

Affiliations

Soon will be listed here.

Abstract

Background: In primary cutaneous melanoma, the sentinel node (SN) biopsy is an accurate method for the staging of the lymph nodes. Positron emission tomography (PET) has been suggested as a useful alternative. However, the sensitivity of PET may be too low to detect SN metastases, which are often small.

Aim: To predict the value of PET for initial lymph node staging in melanoma based on morphometric analysis of SN metastatic load, without exposing patients to PET.

Materials And Methods: In 59 SN positive patients with melanoma, the sizes of tumour deposits in the SNs and subsequent dissection specimens were measured by morphometry and correlated with the detection limits of current and future PET scanners.

Results: The median tumour volume within the basin was 0.15 mm(3) (range, 0.0001-118.86). Seventy per cent of these deposits were smaller than 1 mm(3). State of the art PET scanners that have a resolution of about 5 mm would detect only 15-49% of positive basins. Logistic regression analysis revealed no pretest indicators identifying patients expected to have a positive PET. However, the SN tumour load was a significant and single predictor of the presence of PET detectable residual tumour.

Conclusion: Morphometric analysis of metastatic load predicts that PET scanning is unable to detect most metastatic deposits in sentinel lymph nodes of patients with melanoma because the metastases are often small. Therefore, the SN biopsy remains the preferred method for initial regional staging.

Citing Articles

Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.

Arrangoiz R, Papavasiliou P, Stransky C, Yu J, Tianyu L, Sigurdson E Dermatol Res Pract. 2012; 2012:614349.

PMID: 22654898 PMC: 3359680. DOI: 10.1155/2012/614349.

A review of imaging agent development.

Agdeppa E, Spilker M AAPS J. 2009; 11(2):286-99.

PMID: 19415506 PMC: 2691464. DOI: 10.1208/s12248-009-9104-5.

Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.

Mottaghy F, Sunderkotter C, Schubert R, Wohlfart P, Blumstein N, Neumaier B Eur J Nucl Med Mol Imaging. 2007; 34(9):1355-64.

PMID: 17295038 DOI: 10.1007/s00259-006-0358-1.

Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior?.

Brouwer J, de Bree R, Comans E, Castelijns J, Hoekstra O, Leemans C Eur Arch Otorhinolaryngol. 2003; 261(9):479-83.

PMID: 14685887 DOI: 10.1007/s00405-003-0727-3.

References

Acland K, Healy C, Calonje E, ODoherty M, Nunan T, Page C . Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001; 19(10):2674-8. DOI: 10.1200/JCO.2001.19.10.2674. View

Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R . Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst. 2001; 93(8):630-5. DOI: 10.1093/jnci/93.8.630. View

Statius Muller M, Van Leeuwen P, van Diest P, Vuylsteke R, Pijpers R, Meijer S . No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res. 2001; 11(3):303-7. DOI: 10.1097/00008390-200106000-00013. View

Wagner J, Schauwecker D, Davidson D, Wenck S, Jung S, Hutchins G . FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001; 77(4):237-42. DOI: 10.1002/jso.1102. View

Torrenga H, Licht J, van der Hoeven J, Hoekstra O, Meijer S, van Diest P . Re: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst. 2001; 93(21):1659-61. DOI: 10.1093/jnci/93.21.1659. View

Statius Muller M, van Leeuwen P, van Diest P, Pijpers R, Nijveldt R, Vuylsteke R . Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg. 2002; 26(12):1405-11. DOI: 10.1007/s00268-002-6197-8. View

Gritters L, Francis I, Zasadny K, Wahl R . Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993; 34(9):1420-7. View

Nieweg O . Potential applications of positron emission tomography in surgical oncology. Eur J Surg Oncol. 1994; 20(4):415-24. View

Wagner J, Schauwecker D, Hutchins G, Coleman 3rd J . Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997; 64(3):181-9. DOI: 10.1002/(sici)1096-9098(199703)64:3<181::aid-jso2>3.0.co;2-6. View

10.

Hoh C, Schiepers C, Seltzer M, Gambhir S, Silverman D, Czernin J . PET in oncology: will it replace the other modalities?. Semin Nucl Med. 1997; 27(2):94-106. DOI: 10.1016/s0001-2998(97)80042-6. View

11.

Pijpers R, Borgstein P, Meijer S, Hoekstra O, van Hattum L, Teule G . Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg. 1997; 21(8):788-92; discussion 793. DOI: 10.1007/s002689900307. View

12.

Rinne D, Baum R, Hor G, Kaufmann R . Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998; 82(9):1664-71. DOI: 10.1002/(sici)1097-0142(19980501)82:9<1664::aid-cncr11>3.0.co;2-2. View

13.

Macfarlane D, Sondak V, Johnson T, Wahl R . Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998; 16(5):1770-6. DOI: 10.1200/JCO.1998.16.5.1770. View

14.

Silverman D, Hoh C, Seltzer M, Schiepers C, Cuan G, Gambhir S . Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiat Oncol. 1998; 8(3):183-96. DOI: 10.1016/s1053-4296(98)80044-1. View

15.

Eggermont A . Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eur J Cancer. 1998; 34 Suppl 3:S22-6. DOI: 10.1016/s0959-8049(97)10160-5. View

16.

Mijnhout G, Pijpers R, Hoekstra O, Teule G, Borgstein P, Meijer S . Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1999; 85(5):1199-201. DOI: 10.1002/(sici)1097-0142(19990301)85:5<1199::aid-cncr28>3.0.co;2-1. View

17.

van Diest P, Peterse H, Borgstein P, Hoekstra O, Meijer C . Pathological investigation of sentinel lymph nodes. Eur J Nucl Med. 1999; 26(4 Suppl):S43-9. DOI: 10.1007/s002590050577. View

18.

Wagner J, Schauwecker D, Davidson D, Coleman 3rd J, Saxman S, Hutchins G . Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999; 17(5):1508-15. DOI: 10.1200/JCO.1999.17.5.1508. View

19.

Borgstein P, Meijer S, van Diest P . Are locoregional cutaneous metastases in melanoma predictable?. Ann Surg Oncol. 1999; 6(3):315-21. DOI: 10.1007/s10434-999-0315-x. View

20.

Mastrangelo M . Conference report 3rd International Conference Adjuvant Therapy of Malignant Melanoma. Melanoma Res. 1999; 9(3):306-8. DOI: 10.1097/00008390-199906000-00015. View